Apilimod

Catalog No.S6414 Batch:S641405

Print

Technical Data

Formula

C23H26N6O2
Molecular Weight 418.49 CAS No. 541550-19-0
Solubility (25°C)* In vitro DMSO 84 mg/mL (200.72 mM)
Ethanol 21 mg/mL (50.18 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.2mg/ml Taking the 1 mL working solution as an example, add 50 μL 84 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
Targets
IL-12 [1]
( in IFN-γ/SAC-stimulated human PBMCs)		 IL-12 [1]
(in human monocytes)		 IL-12 [1]
(in mouse PBMCs)		 PIKfyve [1]
1 nM 1 nM 2 nM 14 nM
In vitro

Apilimod selectively inhibits TLR-induced cytokine expression. It selectively inhibits the production of IL12p40, whereas it has little effect on IL8 production in THP-1 cells[1].

Apilimod reduces not only PtdIns(3,5)P2 production but also that of PtdIns5P in intact cells[2].
In vivo

Apilimod is a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HeLa cells

  • Concentrations

    10 nM and 1 μM

  • Incubation Time

    120 min

  • Method

    HeLa cells are metabolically labeled with [3H]inositol for 72 hr and treated with two doses of apilimod or the inactive analog API09 for 120 min. Lipids are extracted, deacetylated, and analyzed by HPLC.
Animal Study:

[4]
  • Animal Models

    Mice

  • Dosages

    50 mg/kg

  • Administration

    p.o.

Selleck's Apilimod has been cited by 16 publications

Inhibition of PIKfyve Leads to Lysosomal Disorders via Dysregulation of mTOR Signaling [ Cells, 2024, 13(11)953] PubMed: 38891085
PIKfyve controls dendritic cell function and tumor immunity [ bioRxiv, 2024, 2024.02.28.582543] PubMed: 38464258
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2 [ bioRxiv, 2024, 2024.04.15.589676] PubMed: 38659941
Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics [ Nucleic Acids Res, 2023, 51(4):1583-1599] PubMed: 36727438
Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage [ Front Immunol, 2023, 14:1128700] PubMed: 37359517
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments [ NPJ Digit Med, 2022, 5(1):18] PubMed: 35165389
Executable network of SARS-CoV-2-host interaction predicts drug combination treatments [ NPJ Digit Med, 2022, 5(1):18] PubMed: 35165389
Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors [ Stem Cell Reports, 2022, 17(2):397-412] PubMed: 35063131
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19 [ Commun Biol, 2022, 5(1):808] PubMed: 35962188
TSC1 binding to lysosomal PIPs is required for TSC complex translocation and mTORC1 regulation [ Mol Cell, 2021, S1097-2765(21)00324-5] PubMed: 33974911

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.